GLAUKOS Corp, a developer of ophthalmic implants and therapies focused on glaucoma and corneal health, reported operating losses for four consecutive years amid incremental product approvals. The company recently launched the iDose TR intracameral implant and Epioxa pharmaceutical therapy, both promising innovations, but commercialization hurdles and supply chain concentration weigh on margins. While raising its 2026 revenue outlook, GLAUKOS retains significant R&D and manufacturing investments. Reimbursement uncertainty, competitive pressures, and regulatory risks remain key factors influencing future growth trajectory and capital allocation decisions.